Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Top Cited Papers
- 6 March 2013
- Vol. 63 (4), 567-577
- https://doi.org/10.1136/gutjnl-2012-302853
Abstract
Background We analysed incidence, predictors, histological features and specific treatment options of anti-tumour necrosis factor α (TNF-α) antibody-induced psoriasiform skin lesions in patients with inflammatory bowel diseases (IBD). Design Patients with IBD were prospectively screened for anti-TNF-induced psoriasiform skin lesions. Patients were genotyped for IL23R and IL12B variants. Skin lesions were examined for infiltrating Th1 and Th17 cells. Patients with severe lesions were treated with the anti-interleukin (IL)-12/IL-23 p40 antibody ustekinumab. Results Among 434 anti-TNF-treated patients with IBD, 21 (4.8%) developed psoriasiform skin lesions. Multiple logistic regression revealed smoking (p=0.007; OR 4.24, 95% CI 1.55 to 13.60) and an increased body mass index (p=0.029; OR 1.12, 95% CI 1.01 to 1.24) as main predictors for these lesions. Nine patients with Crohn's disease and with severe psoriasiform lesions and/or anti-TNF antibody-induced alopecia were successfully treated with the anti-p40-IL-12/IL-23 antibody ustekinumab (response rate 100%). Skin lesions were histologically characterised by infiltrates of IL-17A/IL-22-secreting T helper 17 (Th17) cells and interferon (IFN)-γ-secreting Th1 cells and IFN-α-expressing cells. IL-17A expression was significantly stronger in patients requiring ustekinumab than in patients responding to topical therapy (p=0.001). IL23R genotyping suggests disease-modifying effects of rs11209026 (p.Arg381Gln) and rs7530511 (p.Leu310Pro) in patients requiring ustekinumab. Conclusions New onset psoriasiform skin lesions develop in nearly 5% of anti-TNF-treated patients with IBD. We identified smoking as a main risk factor for developing these lesions. Anti-TNF-induced psoriasiform skin lesions are characterised by Th17 and Th1 cell infiltrates. The number of IL-17A-expressing T cells correlates with the severity of skin lesions. Anti-IL-12/IL-23 antibody therapy is a highly effective therapy for these lesions.Keywords
This publication has 64 references indexed in Scilit:
- Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension StudiesInflammatory Bowel Diseases, 2012
- Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureAlimentary Pharmacology & Therapeutics, 2011
- Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor TherapyClinical Gastroenterology and Hepatology, 2010
- Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's diseaseGut, 2009
- Hepatosplenic T-cell lymphoma in a patient with Crohn's diseaseNature Reviews Gastroenterology & Hepatology, 2009
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 casesJournal of Dermatological Treatment, 2009
- The role of the novel Th17 cytokine IL-26 in intestinal inflammationGut, 2008
- Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype statusInflammatory Bowel Diseases, 2008
- IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migrationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006